AB Fishing Tackle

Main Menu

  • Home
  • Fishing Tackle
  • Fishing Rods
  • Fishing Gear
  • Fishing Equipment
  • Fishing Store

AB Fishing Tackle

Header Banner

AB Fishing Tackle

  • Home
  • Fishing Tackle
  • Fishing Rods
  • Fishing Gear
  • Fishing Equipment
  • Fishing Store
Fishing Store
Home›Fishing Store›Johnson & Johnson Stock: Split-Related Litigation (NYSE:JNJ)

Johnson & Johnson Stock: Split-Related Litigation (NYSE:JNJ)

By Sharon D. Horowitz
January 24, 2022
0
0

JHVEditorial photo/iStock via Getty Images

This article was prepared by Jenny.T in collaboration with JR Research.

Investment thesis

Johnson & Johnson (JNJ) is a pharmaceutical company embroiled in long-term talc litigation worth more than $2 billion. In November 2021, the company announced that the Consumer Health segment would be spun off to provide more sustainable growth for the parent company. In addition, the new company will seek bankruptcy protection for the tens of thousands of lawsuits it currently faces.

JNJ also reported less than satisfactory performance for its COVID-19 vaccine, the demand for which lags massively behind competitors such as Pfizer (PFE) & BioNTech’s (BNTX) Comirnaty and Moderna’s (MRNA) Spikevax. Nonetheless, JNJ’s core performance has been exceptional over the past five years, with the company expected to report more than $100 billion in annual revenue by fiscal year 2023.

We discuss whether investors should add JNJ stock now.

JNJ’s strategic spin-off for its consumer healthcare segment

JNJ spin-off

Investor Presentation

Spinoff from JNJ for its consumer healthcare segment. Source: Alpha Research

In November 2021, JNJ announced that it would split the business into two public companies, with the Consumer Health segment being spun off into a new company. He confirmed a story previously reported by CNBC in July 2021. The general consensus is that the fallout is a logical move, given the lawsuits facing the consumer health segment, worth more than $2 billion in talc-related settlements. Moreover, its overall performance has stagnated over the past ten years, accounting for 24% of revenue. to 14.6 billion dollars in 2010, declining just 16% to $14.1 billion in fiscal 2020. Analysts believe the spin-off will also allow JNJ to accelerate its growth in the pharmaceutical segment, which has doubled in the last ten years, growing from $22.4 billion in revenue in 2010 to $45.6 billion in 2020, at a CAGR of 7.37%.

In July 2021, CNBC reported that JNJ plans to discharge liability related to its ongoing talc-related litigation. In doing so, the newly created company would seek bankruptcy protection put an end to disputes among tens of thousands of lawsuits, previously worth over $4 billion. According to the CNBC article, the “Texas two-step bankruptcy maneuver” has often been used by other companies facing similar litigation, such as paper towel maker Brawny in 2017 and, recently, the maker of OxyContin Purdue Pharma. Purdue Pharma has filed for bankruptcy and agreed to settle its claims of more than $10 billion, a payment well below previous claims of trillions of dollars.

JNJ’s bankruptcy petitions will be heard again in February 2022, where all pending talc-related lawsuits will be temporarily suspended. If bankruptcy were approved by the judge, JNJ would pay more than $2 billion for the talc-related claims. While the company is financially able to pay these claims with its $17.6 billion cash and cash equivalents on its balance sheet in Q3’21, the strategic fallout and bankruptcy protection will help protect JNJ’s future liabilities throughout talc litigation. Moving forward, JNJ’s move is indeed a shrewd maneuver to better defend its future margins and growth in the pharma segment.

Its robust pipeline will increase JNJ’s future revenue

JNJ continues to grow with 76 programs in development. Of these, two new molecular entity (NME) products are in the registration phase, with nine NMEs to be filed before 2023. Among its pipeline, JNJ’s respiratory syncytial virus (RSV) vaccine has shown promise with an efficiency of 80% against Caused by RSV lower respiratory tract diseases in people aged 65 and over on. Additionally, it has also shown 70% efficacy for symptomatic acute respiratory infections caused by RSV. Despite ongoing global Phase 3 clinical trials, we expect JNJ’s RSV vaccine to be a resounding success upon future regulatory approval. The vaccine can be the first US FDA-approved vaccine for RSV, which is the main cause of respiratory diseases such as pneumonia. With a market size of $1.6 billion in 2020, the RSV market is expected to reach $4.2 billion by 2027, at a CAGR of 14.9%.

In addition, the company has multiple partnerships, such as:

Moving forward, guided by JNJ 14 new regulatory submissions by 2025, with sales peaking at $4 billion for each approved therapy. Depending on the timing of regulatory approval and patent expiration, JNJ’s strong pipeline can generate up to $56 billion in additional annual revenue. Additionally, JNJ is looking to further expand its vaccine portfolio with new technologies, such as adenovirus vector technology used in its COVID-19 vaccine, as well as mRNA technology used in PFE/BNTX’s Comirnaty vaccine. . As a result, it is evident that JNJ’s future growth in the pharmaceutical segment will be exceptional.

JNJ saw stellar revenue growth

JNJ revenue and net profit.

JNJ revenue and net profit. Data source: S&P Capital IQ

Over the past five years, JNJ has experienced robust revenue growth at a CAGR of 4.93%. In fiscal 2020, the company reported revenue of $82.5 billion, representing a 0.6% year-over-year increase. During the third quarter of 2021, JNJ recorded revenue of $23.3 billion, representing an increase of 0.1% quarter-on-quarter and 10.7% year-on-year.

The growth is partly attributed to its COVID-19 vaccine, which is expected to account for $2.5 billion in sales in fiscal 2021. However, comparatively, JNJ’s COVID-19 vaccine sales had performed poorly against to those of Pfizer & BioNTech $36 billion community and Moderna Spikevax in the $15 billion to $18 billion range for fiscal 2021. Many vaccinated with a JNJ COVID-19 vaccine for the primary dose switched to other brands for their booster injection. As many as 43% switched to MRNA’s Spikevax while 31% preferred PFE’s Comirnaty, with only 26% adhering to JNJ’s vaccine as a booster. This is in stark contrast to 94% who stayed with MRNA and 96% with PFE for their booster shots. Most cited lower efficiency rates as the reason for the switch, while others were concerned about the rare blood clotting side effects. As a result, we don’t expect JNJ to report massive revenue from its COVID-19 vaccine from 2022.

JNJ Revenue and Net Income Projections.

JNJ Revenue and Net Income Projections. Data source: S&P Capital IQ

For fiscal 2021, JNJ guided total revenue in the range of $92.8 billion to $93.3 billion, adjusting for the impact of currency. It represented a slight upward revision from the low of its revenue forecast for the prior fiscal year 2021 of $92.5 billion to $93.3 billion. Prior to the spin-off, JNJ is expected to report a deceleration in revenue growth to a CAGR of 2.76% over the next five years, with the company expected to reach $100 billion in revenue by fiscal year 2023. We we expect these numbers to revise as the company completes its spin-off within the next 18-24 months. Exiting the stagnant consumer healthcare segment will help drive future growth for the parent company. It is evident that despite the lackluster performance of its COVID-19 vaccine and ongoing talc-related litigation, consensus estimates agree that JNJ has a strong portfolio and a robust pipeline to deliver steady revenue growth to the market. ‘to come up.

So, is JNJ Stock a buy?

Income JNJ EV/Fwd.

Income JNJ EV/Fwd. Data source: S&P Capital IQ

JNJ is currently trading at an EV/NTM turnover of 4.43x, in line with its 3-year average of 4.62x. Analysts also rate JNJ stock as fair value given its capacity and reasonable valuation. Although the company is a mature pharmaceutical company, it is still expected to achieve a decent revenue growth rate over the next five years as shown by its Income EV/Fwd. Additionally, we expect JNJ to report a higher accelerated growth rate once the Consumer Health segment is separated. Therefore, interested investors can take advantage of this opportunity to increase their exposure.

Consequently, we assess JNJ stock to buy.

Related posts:

  1. Federal bankruptcy judge grants sweeping immunity to Sackler family in $ 4.3 billion opioid settlement
  2. bankruptcy proceedings and the recent case of Dondero v. Alvarez & Marsal CRF Management, LLC | law of the free man
  3. Local attorney Marc Dwyer honored with Flagler County Pro Bono Lawyer of the Year Award
  4. Amitabh Bachchan shares video of Abhishek talking about their bankruptcy, how they bounced back: ‘This is how we do it…’
Tagsmarket size
Recent Posts
  • Is MSTR Facing Possible Bankruptcy Following Bitcoin’s Collapse?
  • Fishing Equipment Market Size and Forecast
  • Publishers avoid ‘bankruptcy for reporting the truth’ as ​​government scraps Section 40 court fees for press
  • EJF praises Department of Fisheries for gear directive; calls for more reforms in the fisheries sector
  • india sri lanka news: India to step up aid as Sri Lanka nears bankruptcy
Categories
  • Fishing Equipment
  • Fishing Gear
  • Fishing Rods
  • Fishing Store
  • Fishing Tackle
Archives
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • September 2017
  • July 2017
  • June 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • November 2016
  • October 2016
  • July 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • November 2015
  • May 2015
  • April 2015
  • February 2015
  • January 2015
  • February 2014
  • January 2014
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • November 2012
  • June 2012
  • May 2012
  • May 2011
  • March 2011
  • November 2009
  • July 2007
  • October 2006
  • May 2006
  • Privacy Policy
  • Terms and Conditions